Bris­tol My­ers touts long-term ef­fi­ca­cy of re­cent­ly ac­quired Karuna drug

Fresh off clos­ing its $14 bil­lion ac­qui­si­tion of Karuna Ther­a­peu­tics a few weeks ago, Bris­tol My­ers Squibb is pre­sent­ing long-term da­ta for its new sub­sidiary’s promis­ing schiz­o­phre­nia drug, known as KarXT.

Bris­tol My­ers said KarXT’s ef­fi­ca­cy was main­tained through one year in an open-la­bel ex­ten­sion, pre­sent­ing the da­ta Sat­ur­day at the Schiz­o­phre­nia In­ter­na­tion­al Re­search So­ci­ety con­gress. Ad­di­tion­al­ly, more than 75% of pa­tients who con­tin­ued tak­ing the drug for a year achieved a “clin­i­cal­ly mean­ing­ful” re­sult, BMS se­nior VP of glob­al drug de­vel­op­ment Roland Chen told End­points News.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER